Boston, MA 09/22/2014 (wallstreetpr) – According to reports, Merck & Co., Inc. (NYSE:MRK) and Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) have decided to enter into a worldwide licensing agreement for tildrakizumab, (MK-3222), investigational therapeutic antibody candidate of MRK. Currently, it is going through Phase 3 registration trials for the treatment of a skill element named chronic plaque psoriasis.
Insights of MRK and SUNPHARMA agreement:
Under the terms and conditions of the licensing agreement, Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) will get the rights of using and selling tildrakizumab in all human indications across the globe. In return, it will make a hefty upfront payment of $80 million to MRK. Even after this agreement, Merck & Co., Inc. (NYSE:MRK) will continue putting its efforts in regulatory activities and clinical development. All the expenses incurred on such activities will be funded by SUNPHARMA. As soon as the production of tildrakizumab finishes, SUNPHARMA will take the charge of all the activities including subsequent submissions, manufacturing, post-approval studies, pharmacovigilance and commercialization of the approved product.
MRK is entitled to receive undisclosed payments from SUNPHARMA associated with regulatory approvals and sales milestones. Apart from direct commission, it will also receive various tiered royalties ranging from mid-single digit to excellent percentage on sales. According to Iain Dukes, Senior Vice President, Licensing and Business Development, Merck Research Laboratories, the entire management team is pleased to enter into a license agreement with Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) for development and distribution of tildrakizumab. It will help the company to get rid of chronic plaque psoriasis. During an interview, he said that Merck & Co., Inc. (NYSE:MRK)’s agreement with SUNPHARMA was part of its global initiative to increase R&D activities of the company. Other senior management executives including Kirti Ganorkar also seemed pleased about this deal. She is senior vice president of business development segment at SUNPHARMA. She said that it would help MRK to further focus on research activities to find out clinical solutions of other activities as well.
